R egulated secretion is an essential part of platelet function in hemostasis and thrombosis processes, as well as in inflammation, angiogenesis, wound healing, and the response to invading microbes. 1 Classically, platelets contain 3 types of secretory granule: α-granules, dense granules, and lysosomes. The importance of platelet cargo secretion is highlighted by the existence of bleeding pathologies with granule storage pool deficiencies, such as grey platelet syndrome and Hermansky-Pudlak syndrome, characterized, respectively, by a lack of α-granule or dense granule content. 2, 3 Even though several components of the molecular machinery responsible for platelet secretion have been identified, the underlying mechanisms are not yet fully characterized. Indeed, these secretory processes involve fusion of granules with the plasma membrane and regulatory mechanisms. The fusion of granule with plasma membrane is controlled by SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein receptors); these enable the binding and fusion between secretory vesicles/granules (v-SNAREs) and the plasma/target membrane (t-SNAREs). [4] [5] [6] [7] [8] [9] In platelets, the v-SNAREs VAMP (vesicle-associated membrane proteins) 7 and 8 and the t-SNAREs syntaxin-8, syntaxin-11, and SNAP-23 (synaptosomal-associated protein 23) are predominantly involved in α-granule and dense granule secretion. [10] [11] [12] [13] [14] [15] [16] [17] Furthermore, the formation of SNARE complexes requires chaperone proteins, such as Munc-18-2 and Munc-13-4, which are thought to regulate vesicle tethering and priming before secretion, 8, [18] [19] [20] and granule-membrane docking events are likely controlled by the small GTPases, such as Rab27a/b or Rab8 and their effector Slp4 (synaptotagmin-like protein 4; also called SYTL4 or granuphilin). 6, 21 Nevertheless, a clear mechanistic understanding of these docking events is still lacking. In many nucleated cells, vesicle exocytosis is also controlled by myosins, which interact with actin cytoskeleton during the terminal step of membrane fusion, [22] [23] [24] and by dyneins and kinesins, which interact with microtubules.
The present study evaluated the role of kinesin-1-the archetypal member of the kinesin family-in platelet function. This heterotetrameric protein is composed of 2 heavy subunits (Kif5a, Kif5b, or Kif5c isoforms) and 2 light chains (KLC1, KLC2, KLC3, or KLC4 isoforms). 25 Using Kif5b fl/− /Vav1-Cre cKO (conditional knockout) Kif5b mice lacking Kif5b in endothelial cells and all their hematopoietic lineages, including megakaryocytes and platelets, we showed that kinesin-1 represents a new actor involved in the secretion of α-granules and dense granules from platelets, capable of influencing thrombus stability. Moreover, we identified kinesin-1's molecular partners in platelet secretion and found that kinesin-1 interacts with granule-associated Rab27 protein and the Slp4 adaptor protein in this context.
Materials and Methods

Animal Statement
Housing and experiments were done as recommended by French regulations and the experimental guidelines of the European Community. This project was approved by the ethical committee CEEA26 under the number APAFIS#1758-2015070714343480v2.
Mice
Kif5b
fl/− Vav1-Cre (cKO Kif5b ) mutant and WT (wild type) littermate mice have been described by Munoz et al 26 
Unc13d
Jinx mice (Munc-13-4-deficient mice), 8, 27 and WT C57Bl/6J mice were purchased from the Jackson Laboratory. Males and females were indifferently used. The animals were maintained in pathogen-free conditions and handled according to national and institutional guidelines.
Preparation and Culture of Megakaryocytes
Bone marrow cells were obtained by flushing femurs and tibiae of WT and cKO Kif5b mice, and cells expressing the lineage-specific markers on their surface (Ter119, CD45R/B220, CD4, CD5, CD11b, and Gr-1) were depleted using immunomagnetic beads (sheep antirat IgG Dyna-beads). The remaining population (referred as Lin − cells) was cultured at 37°C in 5% CO 2 in Iscove modified Dulbecco medium supplemented with 15% BIT 9500 serum substitute, α-monothioglycerol, and liposomes (phosphatidyl-choline, cholesterol, and oleic acid) and in the presence of 10 nmol/L recombinant human thrombopoietin (TPO). After 5 days of culture, the cell population was enriched in mature megakaryocytes using a 1.5%/3% BSA gradient under gravity (1 g) for 45 minutes at room temperature. 28 Total mRNAs were extracted from cultured cells with RNeasy mini kit.
Quantitative Real-Time Polymerase Chain Reaction
cDNA was prepared from megakaryocyte and platelet mRNA using SuperScript II and Random primers (Invitrogen 
Preparation of Washed Platelets
For human platelets, venous blood was collected from healthy donors in 10% ACD/A buffer (75 mmol/L sodium citrate, 44 mmol/L citric acid, 136 mmol/L dextrose, and pH 4.5), and washed platelets were prepared as described previously. 29 For murine platelets, mice were anesthetized by intraperitoneal injection of sodium pentobarbital (60 mg/kg), and then whole blood was collected by cardiac puncture into 80 µmol/L PPACK (D-phenylalanyl-prolyl-arginyl chloromethyl ketone) and 10% ACD/C buffer (124 mmol/L sodium citrate, 130 mmol/L citric acid, 110 mmol/L dextrose, and pH 6.5). Isolated platelets were obtained as described previously.
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Bleeding Time
Bleeding time assays were performed on 8-to 12-week-old mice by cutting off the tip of the tail (3 mm from the tip) and immediately immersing it in saline, as described previously. 30 The time taken for the bleeding to stop was then recorded. Tail bleeding was monitored for at least 60 s beyond this time point, to ensure that bleeding did not start again; otherwise it was considered as rebleeding. Tail bleeding assays were stopped at 600 s if the bleeding did not stop.
The tube containing saline with blood was centrifuged (750 g, 15 minutes, room temperature), and red blood cells were lysed by adding distilled water. The optical density was read at 416 nm and compared with a standard curve to determine the volume of blood loss.
Hematologic Analysis
Blood counts were determined with an automatic cell counter (Scil Vet abc Plus; Horiba Medical, France).
Platelet Aggregation
Platelet aggregation was monitored by measuring light transmission through the stirred suspension of washed platelets (3×10 8 37°C using a Chronolog aggregometer (Chrono-log Corporation), as described previously. 30 Platelet aggregation was triggered by several agonists. Representative traces for aggregation were obtained from at least 3 independent experiments. Results are expressed as the percentage change in light transmission with respect to the blank (buffer without platelets), set at 100%.
Platelet Dense Granule Secretion
Dense granule secretion was quantified with an ATP release assay kit. Briefly, platelet aggregation was stopped by adding ice-cold EDTA (16 mmol/L) before centrifugation (12 000 g; 1 minute). Supernatants were then incubated with recombinant firefly luciferase (0.25 mg/mL) and its substrate, D-luciferin (0.5 mmol/L), according to the manufacturer's instructions. Light emission was assessed with a luminometer (Fluoroskan Ascent FL; Thermo LabSystems). Dense granule secretion was expressed as the amount of ATP released (in picomoles) from 3×10 8 platelets.
Serotonin Assay
5-HT (platelet serotonin) was assessed using the Serotonin ELISA kit. The platelet total 5-HT content was assayed in platelet lysate after 4 freeze-thaw cycles.
PF4 Release Assay
PF4 (platelet factor 4) contents within the supernatants after thrombin-activated platelets (9×10 7 platelets) were determined using the PF4 ELISA kit following the manufacturer's instructions.
Flow Cytometry
Washed platelets (3×10 8 per mL) were stimulated with a range of thrombin. After incubation for 10 minutes without stirring, platelets were diluted at 10 8 per mL and incubated with the appropriate fluorophore-conjugated antibodies for 20 minutes at room temperature. The samples were then directly analyzed with an Accuri C6 flow cytometer (BD Biosciences, Le Pont de Claix, France).
Standard Transmission Electron Microscopy
Washed platelets were fixed by incubation for 1 hour at room temperature with 1.25% glutaraldehyde in 0.1 mol/L phosphate buffer, pH 7.2, centrifuged for 10 minutes at 1100 g, and washed once in phosphate buffer. Platelets were kept in 0.2% glutaraldehyde at 4°C until processing for standard transmission electron microscopy analysis of platelet morphology, as described previously. 
Whole-Mount Transmission Electron Microscopy
Small drops of platelet-rich plasma (50 µL) were placed on formvarcoated grids for 5 minutes, rinsed for 3 to 4 s with drops of distilled water, dried from the edge with pieces of filter paper, and waved in the air to remove residual moisture. 32, 33 The grids were inserted into the electron microscope without fixation or staining. The number of dense granules was determined in 140 platelets from WT and cKO Kif5b mice.
Measurement of Intracellular Free Calcium Concentration
Mouse platelets (2×10 7 platelets per mL) were loaded with the Ca 2+ -sensitive dye Oregon Green 488 BAPTA1-AM (1 mmol/L) for 30 minutes at 20°C. Ca 2+ mobilization, induced by thrombin, was analyzed in Ca 2+ -free medium and in the presence of 0.5 mmol/L EGTA using an Accuri C6 flow cytometer. Changes in Ca 2+ signal intensity were calculated as the ratios of fluorescence of activated over nonactivated platelets.
Western Blotting
Washed platelets (300 µL; 3×10 8 per mL) were stimulated with thrombin in an aggregometer. After 3 minutes of stimulation, platelets were lysed in denaturing buffer (50 mmol/L Tris, 100 mmol/L NaCl, 50 mmol/L NaF, 5 mmol/L EDTA, 40 mmol/L β-glycerophosphate, 100 µmol/L phenylarsine oxide, 1% SDS, 5 µg/mL leupeptin, 10 µg/mL aprotinin, and pH 7.4). Proteins were separated by SDSpolyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Membranes were incubated with primary antibodies: rabbit anti-Slp4 (0.26 µg/mL), rabbit anti-Kif5b (1.06 µg/mL), rabbit anti-Rab27 (1 µg/mL), rabbit anti-KLC1 (0.32 µg/mL), rabbit anti-14-3-3 zeta (0.2 µg/mL), rabbit anti-VWF (von Willebrand factor; 3 µg/mL), mouse anti-TSP-1 (thrombospondin-1; 0.3 µg/mL), mouse anti-phosphotyrosine (0.2 µg/mL), rabbit anti-serine-phosphorylated PKC (protein kinase C) substrate (0.2 µg/mL), anti-FLAG M2 (0.4 µg/mL), and anti-GFP antibody (0.4 µg/mL). Immunoreactive bands were visualized with enhanced chemiluminescence detection reagents (Perbio Science) using a G:BOX Chemi XT16 Image System and quantified using Gene Tools, version 4.03.05.0 (Syngene, Cambridge, United Kingdom).
Immunoprecipitation and Immunoblotting
For the immunoprecipitation assay in platelets, resting or thrombinactivated (500 mU/mL; 10 minutes) washed platelets (3 to 5×10 9 ) were lysed in lysis buffer (50 mmol/L HEPES pH 7.4, 150 mmol/L NaCl, 1 mmol/L MgCl 2 , 1% Triton X-100, 5% glycerol) supplemented by 5 mmol/L NaF, 2 mmol/L orthovanadate, 10 µmol/L cantaridine, and 1× protease inhibitor cocktail. Immunoprecipitation was performed with polyclonal rabbit Slp4 antibody (4 µg/mg of total protein) or polyclonal rabbit Kif5b antibody (4 µg/mg of total protein). Anti-Slp4 (0.26 µg/mL), anti-Rab27 (1 µg/mL), and anti-Kif5b (1.06 µg/mL) antibodies were used to develop the Western blots.
For the immunoprecipitation assay in human embryonic kidney (HEK) 293T cell line, the HEK 293T cell line was transfected using the lipofectamine transfection reagent. One day after transfection, cells were lysed in lysis buffer (50 mmol/L HEPES pH 7.4, 150 mmol/L NaCl, 1 mmol/L MgCl 2 , 1% Triton X-100, 10% glycerol) supplemented with 1 EDTA-free protease inhibitor cocktail tablet and phosphatase inhibitors. Immunoprecipitation was performed with anti-FLAG M2 affinity gel (25 µg/mg of total protein) or anti-GFP antibody (4 µg/mL). Anti-M2 (0.4 µg/mL) and anti-GFP (0.4 µg/mL) full length were used to develop the Western blots.
Immunofluorescence Analysis
Glass coverslips were coated with 100 μg/mL human fibrinogen in PBS at 4°C overnight, and wells were blocked with 5% BSA. Washed platelets (5×10 7 platelets per mL) were either not stimulated (resting) or stimulated with ADP (20 µmol/L) to induce full platelet spreading, and then plated to fibrinogen-coated glass coverslips and incubated for 30 minutes at 37°C. After washing, platelets were fixed for 15 minutes with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, blocked with 1% BSA, and stained with primary mouse anti-β tubulin (5 µg/mL), rabbit anti-Kif5b (5.3 µg/mL), mouse anti-CD62P (5 µg/mL), mouse anti-CD63 (5 µg/mL), and appropriate Alexa Fluor-labeled secondary antibodies (4 µg/mL), as mentioned. Finally, the coverslips were mounted to slides, and immunofluorescence images were acquired on a Zeiss LSM700 confocal microscope using a Plan-Apochromat 63×/1.40 Oil DIC M27 lens.
Colocalization analysis was determined by quantification of the percentage of the overlapping of tubulin staining within Kif5b staining using the method described by Bolte et al 34 with the Fiji plugin JACoP. Close proximity analysis between 2 proteins was based on the measure of the distance between 2 fluorescent spots located in a distance inferior to 230 nm, according to the method described previously by de Chaumont et al 35 by using Icy imaging software (http:// icy.bioimageanalysis.org/protocol/colocalizer).
Liquid Chromatography-Tandem Mass Spectrometry
Protein extracts (30 µg) were precipitated with acetone at −20°C during 3 hours and incubated with 20 μL of 25 mmol/L NH 4 HCO 3 containing sequencing-grade trypsin (12.5 μg/mL; Promega) overnight at 37°C. Peptides were desalted using ZipTip µ-C18 Pipette Tips (Millipore) and analyzed in technical triplicates by a Q-Exactive Plus coupled to a Nano-LC Proxeon 1000 equipped with an easy-spray ion source (all from Thermo Scientific). Peptides were separated by chromatography with the following parameters: Acclaim PepMap100 C18 precolumn (2 cm, 75 μm ID, 3 μm, 100 Å), Pepmap-RSLC Proxeon C18 column (50 cm, 75 μm ID, 2 μm, 100 Å), 300 nL/min flow rate, gradient from 95% solvent A (water, 0.1% formic acid) to 35% solvent B (100% acetonitrile, 0.1% formic acid) for a period of 98 minutes, followed by a column regeneration for 23 minutes, giving a total run time of 2 hours. Peptides were analyzed in the Orbitrap cell, in full ion scan mode, at a resolution of 70 000 (at m/z 200), with a mass range of m/z 375 to 1500 and an AGC target of 3×10 6 . Fragments were obtained by high collision-induced dissociation activation with a collisional energy of 30% and a quadrupole isolation window of 1.4 Da. MS/MS data were acquired in the Orbitrap cell in a Top20 mode, at a resolution of 17 500, with an AGC target of 2×10 5 , with a dynamic exclusion of 30 s. MS/MS of the most intense precursor was first acquired. The maximum ion accumulation times were set to 50 ms for MS acquisition and 45 ms for MS/MS acquisition. Label-free relative quantification was performed in between subject analysis with raw data acquired in technical replicates, using Progenesis-Qi software 3.0 (Nonlinear Dynamics, Ltd, Newcastle, United Kingdom) and with the following procedure: (1) chromatograms alignment, (2) peptide abundances normalization, (3) statistical analyses of features, and (4) peptide identification. For this last step, all MS and MS/MS data were processed with the Proteome Discoverer software (version 2.1; Thermo Scientific) coupled to the Mascot search engine (version 5.1; Matrix Science). The mass tolerance was set to 7 ppm for precursor ions and 0.02 Da for fragments. The maximum number of missed cleavages was limited to 2 for the trypsin protease. The SwissProt database (01/2016) with the Mus musculus taxonomy was used for the MS/MS identification step. Peptide identifications were validated using a 1% false discovery rate threshold calculated with the percolator algorithm. Protein abundance variations were measured according to the Hi-3 label-free quantification method (for each protein quantification, only the 3 most abundant peptides were considered).
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In Vitro Thrombus Formation Under Flow Conditions
Thrombus formation was evaluated in a whole-blood perfusion assay on a fibrillar collagen matrix under arterial shear conditions (shear rate of 1200 s −1 ). Glass microcapillary tubes (Vitrocom Hollow Rectangle Capillaries; Fiber Optic Center) were coated with fibrillar collagen (50 µg/mL; overnight at 4°C). Blood from 1 mouse was collected in 80 µmol/L PPACK and fluorescently labeled with rhodamine 6G (10 µg/mL). Labeled whole blood was then perfused through the coated glass microcapillary, at a shear rate of 1200 s −1 for 1 minute with a KD Scientific syringe pump (Fisher Bioblock Scientific), followed by 5 minutes of perfusion with Tyrode buffer (the washing step). Realtime thrombus formation was recorded with an inverted epifluorescence microscope (Nikon Eclipse TE2000-U), coupled to Metamorph 7.0r1 software (Universal Imaging Corporation). Thrombus formation was determined as the mean percentage of the total area covered by thrombi after 1 minute of perfusion and 5 minutes of washing.
FeCl 3 -Induced Thrombosis Model
FeCl 3 injury was induced in 4-to 5-week-old mice, as described previously. 37 To facilitate visualization of thrombus formation, platelets of anesthetized mice were fluorescently labeled in vivo by injection of rhodamine 6G (3.3 mg/kg) into the retro-orbital plexus. After topical deposition on the mesenteric vessels of FeCl 3 solution (10%), thrombus growth was monitored in real-time with an inverted epifluorescent microscope (×10; Nikon Eclipse TE2000-U). If no occlusion was observed after 60 minutes, the occlusion time was recorded as over to 60 minutes.
During the 60-minute observation period, the number of full detachment of thrombus from the vessel wall at the injury site was recorded and counted as embolization events.
Platelet Secretion in Real-Time by Videomicroscopy
The live videomicroscopy was performed using platelets (3×10 7 ) loaded by 20 µmol/L mepacrine. Cells were allowed to attach to poly-l-lysine-coated glass coverslips before stimulation by thrombin (75 mU/mL). Live videomicroscopy images were then acquired for 5 minutes (exposure time, 60 ms). During the observation, the platelets were maintained at 37°C. Fluorescence data were acquired with an Eclipse Ti-E imaging system (Nikon). Images were acquired with a Ropper scientific QuanTEM 512 SC camera and NIS-Elements AR software (version 3.1). Image sets were processed with Icy software. A mepacrine-containing granule was defined by a minimum size of 4 pixels (1 pixel, 0.13 µm) of strong intensity signal, orange to white intensity from the pseudocolor scale.
Statistical Analysis
All analyses of statistical significance were performed with GraphPad Prism software (version 6; GraphPad, Inc, San Diego, CA). If only 2 groups were compared, a Student t test was used, otherwise, for ≥3 groups, a 1-way ANOVA followed by Sidak correction for multiple comparisons was used. Before performing these statistical tests, a D'Agostino-Person normality test was performed to test whether the populations were distributed according to a Gaussian distribution, and then the equality of variances was tested with an F test if a Student t test will be used or with a Bartlett test if an ANOVA will be done.
When data were nonparametric, such as in occlusion time in vessel after FeCl 3 -induced thrombosis, a 2-tailed Mann-Whitney U test was used, and when a statistical significance test was required in an analysis of frequency, such as in frequency of rebleeding, a Fisher exact test was done.
Results
Kif5b Is Expressed in Megakaryocytes and Platelets but Is Not Required for Thrombopoiesis
To investigate the molecular machinery involved in platelet secretion, we focused on Kif5b-the major heavy-chain isoform of kinesin-1 in megakaryocyte lineages-as demonstrated by quantitative PCR ( Figure 1A ). To elucidate, the role of Kif5b in platelet function, we generated a conditional Kif5b-deficient mouse model (Kif5b fl/− /Vav1-Cre; cKO Kif5b ) by crossing a Kif5b fl/− mouse 38 with a Vav1-Cre mouse. These animals lack Kif5b in all their hematopoietic cell lineages (including megakaryocytes and platelets) but do not display any obvious abnormalities in the behavior, development, or maturation of their lymphoid and myeloid lineages. 26 Quantitative real-time PCR assays confirmed the absence of Kif5b in cKO Kif5b megakaryocytes and also the absence of compensatory upregulation of the other isoforms ( Figure 1A ). The absence of Kif5b protein in cKO Kif5b platelets was confirmed by Western blotting ( Figure 1B ). To evaluate hemostatic parameters and identify possible abnormalities of hematopoiesis in cKO Kif5b mice, we performed complete blood counts. No significant difference in platelet, leukocyte, and red blood cell counts, hematocrit or hemoglobin concentration, relative to WT animals was observed (Table) . The cKO Kif5b mice's mean platelet volume was also normal. Transmission electron microscopy showed that the cKO Kif5b platelets had a normal discoid shape, a normal size, and normal organelle counts ( Figure 1C through 1F) . No significant difference in the number, size, or morphology of α-granules was observed. Similarly, no significant difference in the number of dense granules was noticed by whole-mount transmission electron microscopy (WT: 7.7±0.4 dense granules and cKO Kif5b : 8.2±0.6 dense granules; n=140 platelets; Figure 1G and 1H). Taken as a whole, these results indicate that kinesin-1 does not have a crucial role in thrombopoiesis and platelet morphology.
Hemostasis Is Unstable in cKO Kif5b Mice
To investigate Kif5b's involvement in hemostasis and thrombosis in vivo, we first compared the bleeding times of WT and cKO Kif5b mice in a tail-clip assay. Although the bleeding time was similar in the 2 genotypes (Figure 2A ), a significant increase of blood loss (P<0.05; Figure 2B ) and of the frequency to rebleed (29% of animals versus 0% in WT mice; P<0.05; Figure 2C ) was observed in cKO Kif5b mice. We next assessed the in vivo role of Kif5b in a FeCl 3 -induced thrombosis model, using intravital microscopy of mesenteric vessels. We observed that 37% of the cKO Kif5b mice exhibited an abnormal absence of occlusion in venules versus 0% in WT mice (P<0.05; Figure 2D ). Moreover, a higher frequency of embolization of thrombi was noticed in venules of cKO Kif5b mice (50% of animals versus 30% in WT mice) and arterioles (33% of animals versus 17% in WT mice), suggesting that the thrombi formed in cKO Kif5b mice could be less stable over time than those in WT mice. To confirm the in vivo instability of thrombi in these mice, we next assessed adhesion and thrombus formation of cKO Kif5b platelets in a wholeblood perfusion assay over a collagen matrix under blood flow conditions ( Figure 2E ). Just after whole-blood perfusion, the adhesion of cKO Kif5b platelets was similar to that of WT platelets (9.3±0.8% versus 9.1±0.8%, respectively; P=0.99). However, the perfusion of Tyrode buffer over adhered platelets for 5 minutes (the washing step) revealed significantly greater detachment (29.8±1.3% decrease in adhesion; P<0.05) for the cKO Kif5b platelets than for WT platelets (9.7±7.3% decrease in adhesion; P=0.66); this was suggestive of impaired stability in cKO Kif5b platelets.
Given that thrombus formation and platelet aggregation are closely associated, we next evaluated kinesin-1's involvement in aggregation after the activation of washed platelets by several agonists, such as thrombin, collagen, TXA 2 (thromboxane A 2 ) mimetic (U46619), and ADP (Figure 3) . At a low dose of thrombin (50 mU/mL), the aggregation of cKO Kif5b platelets was significantly lower (by 77.5±7.3%; P<0.001) than for WT platelets. At an intermediate dose of thrombin (70 mU/mL), the aggregation of cKO Kif5b platelets was still defective (37.7±6.1%; P<0.001), relative to WT platelets. Aggregation was normal only at a higher dose of agonist (100 mU/mL; Figure 3A) . Similar results were observed for collagen-and U46619-induced aggregations. Indeed, on collagen activation, the aggregation of cKO Kif5b platelets was impaired by 48.8±6.2% versus WT (P<0.001; Figure 3B ) at a low dose of agonist (0.5 µg/mL) but not at a high dose (1 µg/mL), and on U46619 stimulation, the aggregations of cKO Kif5b platelets were only significantly reduced by 64.5±18.7% (P<0.05) and 29.2±2.6% (P<0.01) at low (75 nmol/L) and intermediate (100 nmol/L) concentrations, respectively ( Figure 3C ). Finally, we did not observe any differences of aggregation between WT and cKO Kif5b platelets after activation by low and high ADP concentrations ( Figure 3D ).Taken as a whole, these in vivo and in vitro results demonstrate that kinesin-1 has a role in platelet function and thrombus stability but also suggest a role in platelet secretion. Kif5b platelets was measured in a whole-blood perfusion assay, using a fibrillar collagen matrix, at a shear rate of 1200 s −1 for 1 min, followed by 5 min of perfusion with Tyrode buffer (the washing step). Images represent platelet adhesion before and after the washing step. The graph shows the quantification of platelet adhesion. The results are expressed as the mean±SEM percentage of the total area covered with platelets in 5 independent experiments. Statistical significance was determined in a 1-way ANOVA, followed by Sidak correction for multiple comparisons (*P<0.05). The scale bar corresponds to 50 µm. ns indicates nonsignificant. 
Kinesin-1 Regulates Dense Granule and α-Granule Secretion in Platelets
The release of dense and α-granules from platelets has an essential role in platelet adhesion and aggregation and thrombus stability. We next investigated the role of Kif5b in dense granule secretion by monitoring the release of ATP from platelets during thrombin-induced aggregation ( Figure 4A) . At low doses of agonist (50-70 mU/mL), dense granule secretion was strongly impaired (75±4% and 32±1% of WT, respectively; P<0.001), whereas at higher concentration (100 mU/mL), the impairment was no longer observed. Similar results were obtained after collagen-and U46619-induced platelet activation ( Figure IA in the online-only Data Supplement). Because ADP alone induces extremely weak dense granule secretion of washed platelets, 39 no signal was detected ( Figure IA in the online-only Data Supplement). This defect could not be Figure 4 . Kinesin-1 regulates the secretion of α-granules and dense granules in platelets. A, Dense granule secretion after stimulation by thrombin (50-100 mU/mL) was assessed by measuring ATP release from WT (wild type) platelets and cKO (conditional knockout) Kif5b platelets. The results are expressed as the mean±SEM of ATP released (in picomoles) in at least 3 independent experiments. Statistical significance was determined using an unpaired Student t test (***P<0.001). B and C, Dynamic secretion of dense granules on thrombin activation (75 mU/mL) of mepacrine-labeled WT and cKO Kif5b platelets was observed by real-time videomicroscopy during 300 s. The pseudocolor scale goes from blue (weak staining) to white (intense staining). The scale bars correspond to 0.5 µm. The graph shows the percentage of mepacrine-labeled granules per platelet. Fifteen cells were analyzed for each condition, and an unpaired Student t test was used to determine statistical significance (*P<0.05, ***P<0.001). D, Restoration of thrombin-induced aggregation of cKO Kif5b platelets by a subthreshold concentration of ADP (5 µmol/L). The traces are representative of 3 independent experiments. E and F, Expression of the α-granule membrane marker P-selectin (CD62P) on several thrombin concentrations, in absence (E) or in presence of apyrase (2.5 U/mL) and indomethacin (4.5 µmol/L; F) to prevent the amplification of CD62P exposure by released ADP and synthetized thromboxane A 2 , respectively. The data are quoted as the mean±SEM expression in 8 separate experiments. G, PF4 (platelet factor 4) secretion after stimulation by thrombin (50-100 mU/mL) of WT and cKO Kif5b platelets. PF4 concentrations are expressed as the mean±SEM (n=3). E-G, Statistical significance was determined in a 1-way ANOVA, followed by Sidak correction for multiple comparisons (*P<0.05, **P<0.01, ***P<0.001). ns indicates nonsignificant.
attributed to a lack of dense granule cargo, because similar ATP release was observed at high thrombin concentration (2 U/mL) for WT and cKO Kif5b platelets ( Figure IIA in the onlineonly Data Supplement), and total serotonin content of dense granules was similar in cKO Kif5b and WT platelets (Figure IIB in the online-only Data Supplement). To confirm kinesin-1's role in dense granule secretion, we developed a method to visualize in real-time platelet degranulation by monitoring by videomicroscopy the fluorescence of labeled platelets by mepacrine-a specific marker of dense granules. 40 Although the mepacrine labeling disappeared rapidly after WT platelet activation by thrombin (75 mU/mL), the secretion was significantly delayed in cKO Kif5b platelets (Figure 4B and 4C; Movie I in the online-only Data Supplement). Interestingly, a similar delay of dense granule secretion was also found using Munc-13-4-deficient mice (Unc13d Jinx mice; Figure III in the onlineonly Data Supplement), which exhibit a secretory defect. 8 Taken as a whole, these results clearly show that dense granule release is impaired in cKO Kif5b platelets. ADP release from dense granules constitutes an autocrine signal that amplifies platelet aggregation, notably at low agonist concentrations. Hence, to confirm that defective release of ADP (and thus dense granules) was responsible for the impaired aggregation of cKO Kif5b platelets, we assessed the effect of adding subthreshold concentration of ADP (5 µmol/L) on aggregation induced by a low dose of thrombin (60 mU/mL). Indeed, although ADP alone did not induce platelet aggregation (not shown), the incubation of platelets with ADP reversed the aggregation defect observed in cKO Kif5b platelets by thrombin ( Figure 4D) . Hence, the impaired aggregation was likely because of defective release of dense granule contents, including ADP.
To determine whether kinesin-1 is also involved in α-granule exocytosis, we used flow cytometry to investigate P-selectin (CD62P) surface exposure on thrombin-stimulated cKO Kif5b platelets ( Figure 4E ). Relative to WT platelets, cKO Kif5b platelets displayed significant delays of P-selectin exposure at thrombin concentrations ≤200 mU/mL. Similar results were obtained with collagen ( Figure IB in the onlineonly Data Supplement). Unfortunately, it was not possible to detect P-selectin exposure by U46619, even at high concentration (100 µmol/L). Indeed, even if U46619 induces dense granule secretion and ADP secretion, this released ADP is not able to induce α-granule secretion of washed platelets. 39 These defects in P-selectin exposure were overcome by high dose of thrombin (1 U/mL). Moreover, the quantification by flow cytometry of total CD62P exposure induced by high thrombin concentration (2 U/mL; Figure IIC in the online-only Data Supplement) and the quantification by immunoblotting of VWF and TSP-1 levels ( Figure IID and IIE in the online-only Data Supplement), 2 proteins stored in α-granules, revealed no significant difference between WT and cKO kif5b platelets. Therefore, these data indicate that the defect resulted from impaired exocytosis rather than reduced P-selectin exposure because of defective platelet activation or a lack of α-granule protein contents. Moreover, this defect in α-granule exocytosis was also confirmed by the quantification of PF4 after thrombin-activated platelets ( Figure 4G) . Indeed, PF4 secretion was significantly impaired in cKO Kif5b platelets at low and intermediate doses of thrombin. Because α-granule secretion is strongly dependent on dense granule secretion, 41 we next determined whether kinesin-1 directly acts on α-granule exocytosis or whether the observed defect in CD62P exposure is the consequence of the defect of dense granule secretion in cKO Kif5b platelets. To address this question, we measured P-selectin exposure in the presence of apyrase and indomethacin, to prevent amplification of CD62P exposure by released ADP and synthetized TXA 2 , respectively ( Figure 4F ). Significant delays of P-selectin exposure by cKO Kif5b platelets were still observed, proving the direct involvement of kinesin-1 on α-granule exocytosis ( Figure 4F ).
Taken as a whole, these results demonstrate that kinesin-1 in platelets has a significant role in both the secretion of dense granules and α-granules. Indeed, platelet aggregation defects occurred in cKO Kif5b platelets only when granule secretion was involved.
Secretion Defects in Kif5b-Deficient Platelets Are Not Caused by Impaired Platelet Signaling
To further elucidate the role of Kif5b in platelet function in general and platelet secretion in particular, we hypothesized that kinesin-1 might act directly on the intracellular granule transport.
First, to rule out a possible defect in cell signaling, we evaluated receptor expression and signaling events in cKO Kif5b platelets. Cell surface expression levels of GP (glycoprotein) Ibα, GPVI, and integrin α IIb β 3 and α 2 were found to be normal in cKO Kif5b platelets ( Figure IVA in the online-only Data Supplement). We then looked at whether defective calcium signaling might account for impaired function in cKO Kif5b platelets because calcium mobilization from intracellular stores is essential for platelet activation and secretion. 42 When comparing WT and cKO Kif5b platelets, no significant difference in intracellular calcium mobilization was noted at either low or high doses of thrombin ( Figure IVB in the online-only Data Supplement), indicating a normal calcium signaling in cKO Kif5b platelets. Next, we evaluated PKC activity because PKC family members are significant regulators of platelet function; in particular, the conventional PKC isoform, PKCα, is the main regulator of dense granule secretion. 43 After thrombin activation and the blockade of α IIb β 3 engagement using the Leo.H4 antibody, the serine phosphorylation profile of PKC substrates ( Figure IVC in the online-only Data Supplement) was normal, indicating that the secretion defects were not because of the impairment of PKC signaling by kinesin-1. Similar results were obtained when tyrosine-phosphorylated proteins were investigated ( Figure IVD in the online-only Data Supplement).
Last, we quantified integrin α IIb β 3 activation by using JON/A monoclonal antibody, which binds specifically to activated integrin α IIb β 3 . Whereas cKO Kif5b platelets displayed impaired α IIb β 3 activation at low thrombin concentrations ( Figure IVE in the online-only Data Supplement), in line with the aggregation experiments in Figure 3A , no difference between WT and cKO Kif5b platelets was observed after stimulation with either low or high thrombin concentrations in the presence of apyrase and indomethacin (used to prevent the amplification of integrin activation by released ADP and synthetized TXA 2 , respectively; Figure IVF in the online-only Data Supplement). These results indicate that Kif5b deficiency did not act directly on the integrin activation, but Kif5b modulated this activation via the secretion.
Taken as a whole, the defective secretion observed in cKO Kif5b platelets results from impaired secretion machinery and not from impaired signaling.
Characterization of the Kinesin-1-Dependent Secretory Machinery in Platelets
Given that kinesin-1 is known to interact with Rab27a/b and Slp proteins in nucleated cells, 26, 44, 45 we next investigated whether this interaction could occur in platelets. First, quantitative PCR assays showed that Rab27b was the main Rab27 family member expressed in platelets ( Figure 5A ) and megakaryocytes ( Figure VA in the online-only Data Supplement), whereas Rab27a was expressed at low levels only. Of note that this is in line with the literature data on defective secretion by platelets in Rab27b-deficient mice. 46 Second, analysis of the expression of the 5 Slp members revealed that only Slp4 was strongly expressed in platelets ( Figure 5B ) and megakaryocytes ( Figure VB in the online-only Data Supplement). The presence of Rab27 protein, Slp4, and kinesin-1 was confirmed by a proteomic analysis (Table I in the online-only Data Supplement) and by Western blotting ( Figure 5C ). In addition, coimmunoprecipitation assays indicated that Rab27 and Slp4 were able to interact with kinesin-1 in platelets ( Figure 5D ).
Moreover, Slp4 and Kif5b were coimmunoprecipitated in both resting and thrombin-activated platelet lysates, indicating that the 2 proteins interacted constitutively ( Figure VC and VD in the online-only Data Supplement). Interestingly, this interaction between Slp4, Kif5b, and KLC1 has never been described before. To further identify interactions between proteins in the complex, various combinations of tagged proteins were overexpressed in HEK 293T cells. An interaction between Rab27b and Slp4 was confirmed by coimmunoprecipitation of the 2 proteins ( Figure 5E ). Interestingly, we also confirmed the interaction between Slp4 and the light chain (KLC1; Figure 5F ) and heavy chain (Kif5b; Figure 5G ) of kinesin-1.
Last, we investigated by confocal microscopy the subcellular localization of Kif5b in platelets. To facilitate these observations, we performed immunofluorescence analysis in human platelets instead of murine platelets because human platelets display a better cellular spreading after activation, facilitating colocalization analysis. In resting platelets, endogenous Kif5b was distributed along the marginal band-a circumferential microtubule bundle located beneath the plasma membrane-and within granular structures ( Figure 6A) . A quantification of the colocalization showed an overlapping of 73.8±9.7% of tubulin staining within Kif5b staining, indicating a strong link between the 2 proteins. After activation, Kif5b was mainly found centralized to activated platelets and weakly associated with tubulin labeling (overlapping of 49.7±4.1%). Finally, to further evaluate Kif5b interactions Figure 5 . Characterization of the kinesin-1-dependent secretory machinery in platelets. Real-time polymerase chain reaction quantification of the relative levels of (A) Rab27a and Rab27b transcripts and (B) Slp (synaptotagmin-like protein) 1, Slp2, Slp3, Slp4, and Slp5 in mouse platelets. Transcript levels in each sample were expressed as a proportion of the mean value for Rab27b or for Slp4. C, KLC1 (light chain of kinesin-1), Slp4, and Rab27 expressions in WT (wild type) and cKO (conditional knockout) Kif5b platelet lysates. D, WT platelet lysates (2.5×10 9 ) were immunoprecipitated with a polyclonal anti-Slp4 antibody (IP Slp4) or an isotype control antibody (IP Ctl). The immunoblots were analyzed using anti-Kif5b (kinesin-1 heavy chain), anti-Slp4, and anti-Rab27 antibodies. The data are representative of 3 independent experiments. E-G, Immunoprecipitation analysis of Slp4, Rab27b, and KLC1 in HEK 293T cells coexpressing GFPRab27b and Flag-Slp4 (E), GFP-KLC1 and Flag-Slp4 (F), or GFP-Kif5b and Flag-Slp4 (G). The blots are representative of 3 independent experiments.
with platelet granules, we analyzed its distribution by probing ADP-activated human platelets for the α-granule marker CD62P and the dense granule/lysosome marker CD63 ( Figure 6B and 6C) . The analysis of CD62P/Kif5b and CD63/ Kif5b labelings showed that they were closely located because they were found in a near area after activation. Indeed, the quantification of the distance between 2 fluorescent spots indicated that 41.6±10.1% of CD62P/Kif5b and 51.3±13.2% of CD63/Kif5b were located in a close proximity (distance inferior to 230 nm).
Discussion
In addition to its role in maintaining vascular homeostasis, platelet granule secretion is involved in stabilizing platelet adhesion and promoting thrombus growth and stability. 47 Furthermore, platelet granules contain several chemokines, growth factors, and cytokines 48, 49 with crucial roles in inflammation reactions, wound repair, and vascular remodeling. 50 Accordingly, dysfunctions of platelet secretion can lead to bleeding disorders, thrombosis, and impaired inflammation and immunologic responses. 51 Even though several regulators of the fusion machinery for secretory granule exocytosis have been identified in platelets, the underlying mechanisms are not yet fully characterized. The present study provided in vitro and in vivo evidence to show that the Kif5b heavy-chain isoform of the kinesin-1 is a new actor involved in the mechanisms of the secretion of α-granules and dense granules. We further demonstrated that, independent of platelet activation, kinesin-1 links microtubules to α-granules and dense granules through the molecular machinery composed of the granule-associated Rab27 protein and the Slp4 adaptor protein. Moreover, we showed that (1) Kif5b is not required for thrombopoiesis, platelet morphology, or platelet signaling; (2) the absence of Kif5b does not affect the cargo content; and (3) Kif5b is not involved in the organization of the microtubule (data not shown).
Several lines of evidence indicate that kinesin-1 is critical for the secretion of dense granules because a lack of Kif5b (in cKO kif5b mice) dramatically impaired the release of ATP from granules and slowed the time course of dense granule secretion (visualized by videomicroscopy). The defect in dense granule secretion resulted in impaired platelet aggregation. The aggregation response to many agonists requires an amplification cascade, notably through the release of ADP from dense granules. 52 Here, we confirmed that kinesin-1 has a role in dense granule secretion because the addition of exogenous ADP reversed the aggregation defect in cKO kif5b platelets. We also demonstrated that kinesin-1 is directly involved in α-granule exocytosis, as shown by the delays of P-selectin exposure by cKO Kif5b platelets and the impairment of PF4 secretion. Moreover, it is also accepted that platelet secretion contributes to thrombus formation and stability. 53 Interestingly, cKO kif5b mice increase blood loss and tended to rebleed in a tail-clip assay. In addition, kinesin-1 deficiency displayed a delay of thrombus occlusion and an increased frequency of embolization in a FeCl 3 -induced thrombosis model; these observations suggest that kinesin-1 participates in thrombus stability by acting on granule secretion. Although the in vivo hemostasis defect could not be restricted to a platelet defect because our cKO mice (Kif5b fl/− ; Vav1-Cre) were under the control of the Vav1 promoter, which is also expressed in endothelial cells, 54 all the in vitro experiments (platelet aggregations, platelet adhesion under flow, and platelet secretion) confirmed the involvement of platelet kinesin-1 in the secretion of α-granules and dense granules. Nevertheless, further future study should clarify the role of kinesin-1 in endothelial cells and whether kif5b-deficient endothelial cell could impact the thrombotic responses.
It is noteworthy that in the absence of Kif5b, the release of α-granule and dense granule contents was only partially impaired, notably at low concentrations of agonist. Interestingly, this partial defect was not restricted to -deficient mice because several studies have reported mice with secretory defects, such as Munc-13-4-deficient mice 8 or Rab27b-deficient mice 46 that also exhibited defects of platelet aggregation at low doses of agonist and that were overcome at higher concentrations. To explain this partial defect noticed in our murine model, different hypotheses can be advanced. First, because the expressions of Rab27 and Slp4 were normal in cKO kif5b mice, the mechanisms of fusion of the granules with the plasma membrane can occur normally, and thus, 3 mechanisms could be involved: one partially dependent of kinesin-1/Rab27/Slp4 complex; another, independent of kinesin-1 but still involving Rab27/Slp4 complex; and a third one independent of kinesin-1/Rab27/Slp4 complex. Indeed, we cannot exclude that kinesin-1 could participate to other molecular complexes involving Slp4 and Rab8, described previously by Hampson et al, 6 that could be elucidated in future studies. The second hypothesis to explain the absence of strong defect associated to kinesin-1 deficiency in platelet is that kinesin-1 could participate to granule secretion only during the early phase of signaling events, before a full platelet activation, which is associated to cytoskeletal reorganization and platelet shape change, leading to the centralization of the granules. The relocalization of the granules to a limited central area can facilitate a direct fusion of the granules with channels of the surface-connected open canalicular system, 55 which limits the requirement for kinesin-1-dependent granule secretion. Furthermore, recent research has shown that 2 types of fusion occur in platelets: single exocytosis of α-granules and dense granules predominates in moderately stimulated platelets, whereas compound exocytosis (during which only α-granules fuse with each other before reaching the plasma membrane) predominates in strongly stimulated platelets. 56 These sequential fusion events may facilitate the release of α-granule contents by limiting vesicle trafficking before fusion with the plasma membrane. The third hypothesis is that we cannot exclude that kinesin family members other than kinesin-1 could also regulate granule secretion in platelets and could partially compensate for the loss of kinesin-1. In our proteomic analysis study (Table I in the online-only Data Supplement), we detected Kif2a (good score) and Kif13a (weak score), which belong to kinesin-13 and kinesin-3 families, respectively. In the literature, kinesin-13 has been described to be nonmotile and to induce microtubule depolymerization by disassembly tubulin subunits during mitosis. 57 Therefore, it does not seem to be an appropriate candidate for complementing the loss of Kif5b. In contrast, Kif13a could be more appropriate because Kif13a was described as a molecular motor capable to drive the transport of vesicles. 58 However, we found that Kif13a was 25-fold less abundant than Kif5b, suggesting that, if Kif13a compensates Kif5b deficiency, this compensation could only be partial. Moreover, to our knowledge, no link between Rab27 and Kif13a has been described in the literature yet. Finally, we found that the hemostasis defect in cKO Kif5b mice was less marked in vivo than in vitro. This difference could be explained by the in vivo involvement of high local concentrations of agonists, thus bypassing the secretory defect. Indeed, the in vitro defects in platelet secretion and aggregation were reversed by high doses of agonist. Kinesin-1 was described previously in nucleated cells as a molecular motor allowing granule cargo along microtubule network. 59 Our results show a role of kinesin-1 in platelet secretion, but for the moment, we cannot affirm whether kinesin-1 plays an active role in platelet granule transport toward the exocytosis site or whether kinesin-1 plays an indirect role by modulating secretion, granule fusion, or both by an unknown mechanism, and thus, in this case, more investigations will be required. Otherwise, Richardson et al 60 have suggested that kinesin could be likely responsible for transporting organelles and granules along microtubules toward proplatelet formation. Our data indicate normal platelet size, normal organelle counts, normal α-granule and dense granule counts, suggesting that kinesin-1 is not involved in thrombopoiesis. Therefore, another member of kinesin family could be involved in granule transport to proplatelets.
In our study, we showed that a small GTPase Rab27 was one of the molecular partners of kinesin-1. Unfortunately, because of the absence by the antibody to distinguish between Rab27a and Rab27b, we were not able to affirm that the main partner of Kif5b was Rab27b. Nevertheless, literature data strongly argue in favor of a role of Rab27b instead of Rab27a. Indeed, the role of Rab27a in platelet function was discredited several years ago in the studies by Barral et al 61 and Tolmachova et al. 46 In the last study, they have shown that (1) Rab27b knockout mice exhibited defects in platelet function, in contrast to the ashen mice (natural Rab27a-deficient strain) and (2) double KO (knockout; Rab27 ash/ash /Rab27b −/− ) did not exacerbate the defect observed in Rab27b-deficient platelets.
Moreover, it has been reported that Rab27b regulates the number and secretion of dense granules in platelets. 46 Unlike cKO kif5b mice, Rab27b-deficient mice exhibit a severe bleeding defect and have half the normal number of dense granules, while α-granule secretion is normal. If Kif5b and Rab27b interact and have a crucial role in platelet secretion, how can this phenotypic difference be explained? In fact, this discrepancy may be related to (1) Rab27b's broader role in dense granule biogenesis or packaging in proplatelets and (2) the mice's differing genetic backgrounds. Rab27 proteins are known to regulate the transition from microtubule-mediated to actin-mediated transport or to the vesicle transport along the peripheral actin cytoskeleton in various cell types, including melanocytes, pancreatic β-cells, and endothelial cells [62] [63] [64] ; this suggests that Rab27b regulates functions in platelets that do not involve kinesin-1 and so might explain the more profound platelet defect in Rab27b deficiency. Unlike Rab27b's relationship with dense granules, its relationship with α-granules is less well defined. Indeed, although some studies have shown that Rab27b is mainly localized in the limiting membranes of α-granules, 61, 65 its involvement in α-granule secretion has not been unambiguously demonstrated.
Of the 5 different Slp proteins known to interact with the GTP-bound form of Rab27a and Rab27b, 66, 67 we found that Slp4 was predominantly expressed in megakaryocytes and platelets. Here, we observed a previously unknown, activation-independent interaction between Slp4 and kinesin-1 in platelets. In contrast to the situation in mast cells, where kinesin-1 is recruited to the Rab27b/Slp3 complex on activation, 26 it seems that the complex in platelets is already preformed. This may correspond to the requirement for rapid granule release.
Furthermore, a recent study showed that the SNARE VAMP-7 regulates the link between α-granule/dense granule secretion and actin reorganization by interacting with the VARP (VPS9-domain ankyrin repeat protein) and Arp2/3. 14 Interestingly, VARP is also known to be an effector for kinesin-1's Kif5 heavy chains. 68 Future research should seek to determine whether the molecular trafficking complex Rab27/ Slp4/kinesin-1 can interact with VARP and whether formation of the complex depends on platelet activation. Given that platelet activation dissociates VARP from VAMP-7 and ARP2/3, it would be interesting to study the putative effect of VARP/kinesin-1 complex formation on platelet function.
Studies from the past have shown a controversial role of microtubules in regulating platelet secretion. [69] [70] [71] [72] [73] Our recent study has highlighted the role of the microtubule-dependent motor protein kinesin-1 to participate to the secretion of α-granules and dense granules. As it is known that kinesin-1 allows the anterograde movement going from the minus (−) end to the plus (+) end of the microtubule, future study should assess again the requirement of microtubule in the secretion process of platelet.
Last, Diagouraga et al 74 and Sadoul et al 75 have shown that reorganization of the cytoskeleton during platelet activation requires precise coordination; a balance between the kinesin and dynein families is required to keep the marginal band in the resting state. In the present study, kinesin-1 deficiency was not associated with defects in platelet morphology, suggesting that maintenance of the platelet's discoid shape mainly involves the dynein family or kinesins other than kinesin-1. Furthermore, the loss of Kif5b did not affect platelet spreading, the length of the marginal band in resting platelets, and the tubulin reorganization after platelet activation (data not shown), suggesting that Kif5b is not involved in the organization of the microtubule network.
In conclusion, the present study demonstrated that kinesin-1 plays a role in platelet function, stabilization, and regulation of α-granule and dense granule secretion by interaction with the Rab27/Slp4 complex. Overall, our results provide a better understanding of the molecular mechanisms that regulate platelet secretion-a crucial hemostatic function-and suggest the existence of novel pharmacological targets to regulate platelet secretion, in particular, in the context of thrombotic risk.
